In Vitro Activity of Eravacycline against 2213 Gram-Negative and 2424 Gram-Positive Bacterial Pathogens Isolated in Canadian Hospital Laboratories: CANWARD Surveillance Study 2014 –2015

Gram-negative (n=2213) and Gram-positive (n=2424) pathogens isolated from patients in 13 Canadian hospitals in 2014 and 2015 were tested for in vitro susceptibility to eravacycline, and comparators using the Clinical and Laboratory Standards Institute CLSI broth microdilution method. The concentration of eravacycline inhibiting 90% of isolates (MIC90) ranged from 0.5 to 2 μg/mL for 9 species of Enterobacteriaceae tested (n=2067). Eravacycline activity was largely unaffected by ESBL phenotypes in Escherichia coli (n=141) and Klebsiella pneumoniae (n=21).

Source: Diagnostic Microbiology and Infectious Disease - December 21, 2017 Category: Microbiology Authors: George G. Zhanel, Melanie R. Baxter, Heather J. Adam, Joyce Sutcliffe, James A. Karlowsky Source Type: research